We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reengineering Clinical Operations in a Medical Practice to Optimize the Management of Anemia of Chronic Kidney Disease.
- Authors
Joy, Melanie S.; Candiani, Corina; Vaillancourt, Beverly A.; Hyunsook Chin; Hogan, Susan L.; Falk, Ronald J.
- Abstract
Objectives. To describe the clinic design, clinical evaluations, and treatment approaches used in a multidisciplinary clinic for management of anemia of chronic kidney disease (CKD), and to evaluate several selected clinical outcomes associated with this approach to anemia management. Setting. University-affiliated, division of nephrology, outpatient multidisciplinary model CKD clinic headed by a clinical pharmacist. Patients. One hundred sixty-six patients with anemia of CKD who were referred by nephrologists and primary care providers to the multidisciplinary clinic from March 1, 2002-July 31, 2004. Measurements and Main Results. Patients received darbepoetin alfa dosed on an every-other-week basis. If patients were already receiving once-weekly recombinant human erythropoietin (r-HuEPO), the darbepoetin alfa dose was calculated by using the darbepoetin alfa package insert conversion table. If patients were naive to previous erythropoietic therapy, the darbepoetin alfa dose was either 60 µg or 0.7 µg/kg. The dose and frequency of darbepoetin alfa and oral iron supplements were adjusted to achieve the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) targets for hemoglobin levels and iron measures. The primary outcome analyzed was the proportion of patients with at least 30 days of treatment who achieved a target hemoglobin level of 11.0 g/dl or greater. Of 128 patients who received at least 30 days of treatment, 100 (78%) attained the hemoglobin level (mean ± SD 11.7 ± 7 g/dl). Ninety-nine of 128 patients were originally naive to erythropoietic therapy; 77 (78%) of these 99 patients achieved the hemoglobin target in a mean ± SD of 7.9 ± 7.5 weeks. These data contrast with the data of 29 patients seen in the year previous to the reengineered clinic process, whereby only 12 (41%) of these comparable patients reached hemoglobin target with r-HuEPO therapy. Of the 77 previously erythropoietic-naive patients, 82% were receiving darbepoetin alfa every other week, 14% every 3 weeks, and 4% every 4 weeks at the time the hemoglobin target was achieved. Oral iron administration significantly increased the chance of achieving the K/DOQI targets for hemoglobin and iron. Conclusion. Redefining roles and practices of members of a clinical practice and reengineering processes for anemia management were effective in achieving and maintaining target hemoglobin and iron levels.
- Subjects
KIDNEY diseases; ANEMIA; NEPHROLOGISTS; NATIONAL Kidney Foundation Inc.; HEMOGLOBINS
- Publication
Pharmacotherapy, 2007, Vol 27, Issue 5, p734
- ISSN
0277-0008
- Publication type
Article
- DOI
10.1592/phco.27.5.734